Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
14:44:23 EDT Sat 15 Aug 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:NVCR - NOVOCURE LTD - https://www.novocure.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NVCR - Q1.416.55·85.000.116.95-0.43-2.5681.311,1567,30617.23  17.23  16.8021.355  9.8219:39:18Jul 2315 min RT 2¢

Recent Trades - Last 10 of 7306
Time ETExPriceChangeVolume
19:39:18Q17.16-0.221
19:34:07Q17.28-0.101
19:34:03Q17.28-0.101
19:33:57Q17.16-0.2216
19:30:04Q17.16-0.221
19:17:59Q17.28-0.10100
17:01:59Q16.71-0.672
16:20:00Q16.95-0.4319
16:10:05Q16.95-0.431
16:10:05Q16.95-0.431

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-07-23 07:00U:NVCRNews ReleaseNovocure Reports Second Quarter 2026 Financial Results
2026-07-01 07:00U:NVCRNews ReleaseNovocure to Report Second Quarter 2026 Financial Results
2026-06-30 07:00U:NVCRNews ReleaseNovocure's Optune Pax(TM) Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
2026-06-18 07:00U:NVCRNews ReleaseNovocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma
2026-04-30 07:00U:NVCRNews ReleaseNovocure Reports First Quarter 2026 Financial Results
2026-04-01 07:00U:NVCRNews ReleaseNovocure to Report First Quarter 2026 Financial Results
2026-03-26 07:00U:NVCRNews ReleaseNovocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer
2026-03-02 07:00U:NVCRNews ReleaseNovocure Announces Optune Lua(TM) Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
2026-02-27 16:30U:NVCRNews ReleaseNovocure to Participate in 2026 Leerink Global Healthcare Conference
2026-02-26 07:00U:NVCRNews ReleaseNovocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
2026-02-24 07:00U:NVCRNews ReleaseTumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)
2026-02-11 17:54U:NVCRNews ReleaseU.S. FDA Approves Novocure's Optune Pax(TM) for the Treatment of Locally Advanced Pancreatic Cancer
2026-01-12 07:00U:NVCRNews ReleaseNovocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update
2025-12-22 07:00U:NVCRNews ReleaseNovocure to Present at 44th Annual J.P. Morgan Healthcare Conference
2025-12-01 07:00U:NVCRNews ReleaseNovocure Appoints Company President Frank Leonard as Chief Executive Officer
2025-11-26 07:00U:NVCRNews ReleaseNovocure to Participate in 37th Annual Piper Sandler Healthcare Conference
2025-11-12 07:00U:NVCRNews ReleaseNovocure to Participate in 2025 Jefferies Global Healthcare Conference
2025-10-30 07:00U:NVCRNews ReleaseNovocure Reports Third Quarter 2025 Financial Results
2025-10-15 07:00U:NVCRNews ReleaseNovocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress
2025-10-01 07:00U:NVCRNews ReleaseNovocure to Report Third Quarter 2025 Financial Results